Analytics Brief
CORA Signals No. 01
Of 2,367 unique inbound leads captured through the CORA screener between January 2025 and April 2026, 86.3% meet the clinical bar for GLP-1 therapy today, and 57.8% are warm on every dimension: obese, plateaued, and already medicalized with a primary care physician. This is not a weight-loss-curious audience; it is a clinical-treatment audience arriving pre-qualified.
A dedicated "Second Chance" intake protocol (pharmacotherapy, RD, behavioral support, quarterly labs) converts this cohort with almost no creative spend. They are actively searching.
| Age | N | Avg BMI | GLP-1 eligible | Diabetes / pre-DM | Pain limits movement | Depression ≥ 3 |
|---|---|---|---|---|---|---|
| 18 – 24 | 119 | 36.6 | 82% | 21% | 27% | 43% |
| 25 – 34 | 419 | 38.3 | 86% | 19% | 34% | 42% |
| 35 – 44 | 595 | 37.6 | 85% | 21% | 40% | 36% |
| 45 – 54 | 571 | 36.4 | 87% | 36% | 48% | 31% |
| 55 – 64 | 376 | 35.8 | 87% | 43% | 55% | 29% |
| 65 – 74 | 179 | 34.9 | 91% | 40% | 55% | 26% |
| 75+ | 18 | 33.6 | 83% | 28% | 72% | 22% |
44% report pain that limits movement. An undifferentiated "exercise plan" is clinically inappropriate for nearly half the cohort; they need a functional-movement or physical-therapy assessment before any progressive activity prescription.
34% cross a single-item depression threshold (≥3 on a 0–4 self-rating); 20% cross the same threshold on anhedonia; 16% are positive on both. These are screening flags, not clinical diagnoses, but the dual flag is a PHQ-2-style signal worth escalating. 56% already report a therapy history, suggesting receptivity to behavioral support rather than resistance to it.
73% self-rate ≥3 on a 0–4 accountability-need scale, and 50% select the maximum 4. Every program that looks like a subscription and feels like a subscription loses this cohort. Programs that feel like care (scheduled check-ins, named clinicians, personal goals) win it.
| Clinic | Leads | avg BMI | % DM | % prior Rx |
|---|---|---|---|---|
| Bel Air, MD | 164 | 36.7 | 28.0% | 28.0% |
| White Marsh, MD | 154 | 38.2 | 34.4% | 39.0% |
| Bowie, MD | 124 | 37.7 | 46.8% | 32.3% |
| Westminster, MD | 119 | 35.5 | 22.7% | 34.5% |
| Charlotte – Pineville, NC | 113 | 36.0 | 31.9% | 44.2% |
| Pasadena, MD | 110 | 38.4 | 20.9% | 43.6% |
| Charlotte – Ballantyne, NC | 108 | 34.2 | 33.3% | 38.0% |
| Waldorf, MD | 105 | 37.4 | 39.0% | 35.2% |
| Owings Mills, MD | 103 | 38.9 | 35.9% | 34.0% |
| Easton, MD | 102 | 35.6 | 22.5% | 30.4% |
| Odenton, MD | 87 | 36.6 | 37.9% | 35.6% |
| Salisbury, NC | 84 | 37.9 | 25.0% | 41.7% |
| Kernersville, NC | 83 | 36.9 | 27.7% | 42.2% |
| Annapolis, MD | 82 | 36.0 | 23.2% | 30.5% |
| Salisbury, MD | 80 | 37.9 | 23.8% | 20.0% |
On CoreLife's own follow-up survey, the "overall health improvement" item averages 1.49 / 4; only 24% rate improvement at ≥ 3. Composite across the three valid items is 1.31 / 4 (the fourth, "reduced prescriptions because of CoreLife," is not collecting responses). Raw intake is excellent; downstream engagement is where value is leaking.
Section 0334.7% of leads (789) have used a prescription weight-loss medication. Given GLP-1 category dominance since 2023, most recent cases are likely lapsed-GLP-1, but the CORA field is drug-agnostic. Add one follow-up question (which drug, why stopped) so the program can route lapsed-GLP-1 separately from phentermine-era rebound.
Section 04121 rebound leads. BMI 37.7, 56% considering surgery again, 87% plateaued, 40% crossing the depression threshold. This is the most distressed, highest-intent niche, at roughly seven leads a month: a premium micro-program, not a volume channel. Price the wrap-around (RD, behavioral, labs) for LTV, not CAC.
Section 0660% high-stress, 44% in pain, 34% flag on depression, 20% on anhedonia. CORA already collects five mood items and four functional items: a PHQ-2-style depression+anhedonia flag (16% positive on both) is in hand, complemented by stress and isolation prompts. Don't bolt on new screeners; score, threshold, and define a clinical escalation path for what is already collected. Lead creative with stress, not depression: nearly twice the prevalence.
Section 05The age gradient is sharp: under-35 runs 42% depressed, 68% high-stress, 12% on cardiometabolic meds; 55+ runs 25% depressed, 35% stressed, 65–80% on meds. Under 35: mood, confidence, prevention. Over 45: medication load, mobility, comorbidity management. One creative does not optimize both ends.
Section 08Existing-patient self-rated improvement averages 1.31 / 4 across the three CoreLife-benefit items with valid data (overall health 1.49, PCP engagement 1.08, family involvement 1.37). N=90 and likely engaged-biased; the fourth item ("reduced Rx because of CoreLife") returned zero responses, meaning collection for that item is broken. Fix the survey, then deploy longitudinal RTM-style check-ins. Retention is where value leaks.
Section 08Q1'26 (Jan–Mar, 338 leads) ran at 60% of Q1'25 (566). Severity markers drifted up modestly (BMI ≥40 +2.4pp, pain +3.4pp, prior Rx +1.9pp); the arriving cohort is heavier, not absent. A plausible hypothesis is funnel erosion to retail GLP-1 (Ro, Hims, WW/Sequence), but CORA alone cannot test it. Audit SEO, paid, and referral channels before the next media dollar is committed.
Section 0229.5% diabetic or pre-diabetic, 39% on BP, diabetes, or cholesterol medication, concentrated in the 45+ cohort (36–43% DM, 48–80% on meds). Comorbid supervision is exactly where CoreLife beats a retail-GLP-1 script pad. Package a distinct track with T2D plus obesity coding, supervised titration, and PCP co-management: payer-covered, clinically differentiated, retention-favorable.
Section 0293% saw a physician in the last 12 months; 83% already discussed weight with that PCP. The warm-handoff network exists; it is not being monetized. Build a PCP co-sign and shared-outcomes program; every enrolled patient then compounds into the local primary-care referral base, reversing paid-acquisition dependency.
Section 0285% want a structured meal plan; 84% want a therapeutic exercise program designed for them. Both are attach-rate and retention levers, and the physical infrastructure is the moat against retail GLP-1 (Ro, Hims, WW/Sequence). Price-anchor on the bundle (Rx + RD + facility), not on the prescription alone.
Section 05The u35 cohort (N=538, 23.6% of leads) carries BMI 37.9 but only 19% DM, 12% on cardiometabolic meds, and 21% considering surgery, while 42% flag on depression and 68% on stress. They are shopping for confidence, prevention, and mood rather than comorbid management. Package a lower-intensity, mental-health-scaffolded offering priced to the lighter clinical load; do not route them into the 45+ medical track.